PRKAA2 and metabolic dysfunction-associated steatotic liver disease: In NAFLD patients and mouse models, elevated miR-34a, miR-122, miR141 and miR-506-3p levels were reported to promote hepatic steatosis by targeting SIRT1, causing decreased LKB1/AMPK function in the liver28,29,52,53.